alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
I 

118TH CONGRESS 

2D SESSION H. R. 7345 

To amend the Congressional Budget Act of 1974 to modify the rules with 

respect to the consideration in the House of Representatives of any 

resolution providing for an adjournment period of more than three calendar days during the month of July or August until the House of 

Representatives has approved annual appropriation bills, and for other 

purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 14, 2024 

Mr. BRECHEEN (for himself and Mr. KILMER) introduced the following bill; 

which was referred to the Committee on Rules, and in addition to the 

Committee on the Budget, for a period to be subsequently determined by 

the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To amend the Congressional Budget Act of 1974 to modify 

the rules with respect to the consideration in the House 

of Representatives of any resolution providing for an 

adjournment period of more than three calendar days 

during the month of July or August until the House 

of Representatives has approved annual appropriation 

bills, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7345 IH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Waiving the Rules Dis3 closure, Transparency, and Accountability Act’’. 

4 SEC. 2. COMPLETION OF HOUSE ACTION ON REGULAR AP5 PROPRIATION BILLS. 

6 Section 309 of the Congressional Budget Act of 1974 

7 (2 U.S.C. 640) is amended— 

8 (1) by striking ‘‘It shall not be in order’’ and 

9 inserting ‘‘(a) IN GENERAL—It shall not be in 

10 order’’; 

11 (2) by inserting ‘‘or August’’ after ‘‘July’’; and 

12 (3) by adding at the end the following: 

13 ‘‘(b) ENFORCEMENT IN THE HOUSE OF REPRESENT14 ATIVES.—It shall not be in order in the House of Rep15 resentatives to consider a rule or order that waives the 

16 application of subsection (a). 

17 ‘‘(c) QUESTION OF CONSIDERATION.—As disposition 

18 of a point of order under subsection (b), the Chair shall 

19 put the question of consideration with respect to the rule 

20 or order, as applicable. 

21 ‘‘(d) DEBATE AND INTERVENING MOTIONS.—A ques22 tion of consideration under this section shall be debatable 

23 for 10 minutes by the Member initiating the point of order 

24 and for 10 minutes by an opponent, but shall otherwise 

25 be decided without intervening motion.’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
**EXHIBIT 32.2****CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350**     Pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002,I, David Thompson, Secretary and Chief Financial Officer, certify that:1. To my knowledge, this report fully complies with the requirements of Section 13(a) or 15(d) ofthe Securities Exchange Act of 1934; and2. To my knowledge, the information in this report fairly presents, in all material respects, thefinancial condition and results of operations of International Absorbents Inc. as of October 31,2006.   Date: December 8, 2006 /s/ DAVID THOMPSON     David Thompson  *Secretary and Chief Financial Officer*
§ 20.117 New drug information. ( a ) The following computer printouts are available for public inspection in the Food and Drug Administration's Freedom of Information Public Room: ( 1 ) A numerical listing of all new drug applications and abbreviated new drug applications approved since 1938, showing the NDA number, the trade name, the applicant, the approval date, and, where applicable, the date the approval was withdrawn and the date the Food and Drug Administration was notified that marketing of the product was discontinued.
( 2 ) A numerical listing of all new drug applications and abbreviated new drug applications approved since 1938 which are still approved, showing the same information as is specified in paragraph (a)(1) of this section except that it does not show a withdrawal date.
( 3 ) A listing of new drug applications, abbreviated new drug applications, which were approved since 1938 and which are still approved, covering marketed prescription drug products except prescription drug products covered by applications deemed approved under the Drug Amendments of 1962 and not yet determined to be effective in the Drug Efficacy Study Implementation program. The listing includes the name of the active ingredient, the type of dosage form, the route of administration, the trade name of the product, the name of the application holder, and the strength or potency of the product. The listing also includes, for each active ingredient in a particular dosage form for which there is more than one approved application, an evaluation of the therapeutic equivalence of the drug products covered by such applications.
( b ) Other computer printouts containing IND and NDA information are available to the extent that they do not reveal data or information prohibited from disclosure under §§ 20.61, 312.130, and 314.430 of this chapter.
[42 FR 15616, Mar. 22, 1977, as amended at 45 FR 72608, Oct. 31, 1980; 46 FR 8457, Jan. 27, 1981; 54 FR 9038, Mar. 3, 1989; 64 FR 399, Jan. 5, 1999]
UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D.C. 20549





FORM 8-K





CURRENT REPORT


PURSUANT TO SECTION 13 OR 15(d)


OF THE SECURITIES EXCHANGE ACT OF 1934





Date of report (Date of earliest event reported)


August 24, 2017





PATTERSON COMPANIES, INC.


(Exact Name of Registrant as Specified in Its Charter)





Minnesota0-2057241-0886515(State or Other Jurisdictionof Incorporation)(CommissionFile Number)(IRS EmployerIdentification No.)


1031 Mendota Heights Road


St. Paul, Minnesota 55120


(Address of Principal Executive Offices, including Zip Code)


(651) 686-1600


(Registrant’s Telephone Number, including Area Code)





Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


oEmerging growth company





If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o











---




Item 2.02RESULTS OF OPERATIONS AND FINANCIAL CONDITION


On August 24, 2017, Patterson Companies, Inc. issued a press release announcing its financial results for the first quarter of fiscal year 2018 ended July 29, 2017. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.





Item 9.01FINANCIAL STATEMENTS AND EXHIBITS





|    |         
|--- | --------
|(d) | EXHIBITS




99.1Press release of Patterson Companies, Inc., dated August 24, 2017.








---




SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.





PATTERSON COMPANIES, INC.Date: August 24, 2017By:/s/ Ann B. GuginoAnn B. GuginoExecutive Vice President, Chief Financial Officer and Treasurer(Principal Financial and Accounting Officer)








---




EXHIBIT INDEX





ExhibitNumberDescription99.1Press release of Patterson Companies, Inc., dated August 24, 2017.
Court of Appeals

of the State of Georgia

ATLANTA,____________________

The Court of Appeals hereby passes the following order:

A22A0061, A22A0163. James Boyd v. Ruby Chester et al.; and vice versa.

We granted James Boyd’s application for interlocutory review of the trial

court’s order denying his motion to enforce a settlement agreement. After careful

review of the entire record, we conclude that the application for interlocutory appeal

was improvidently granted, and it is ordered that the appeal in Case No. A22A0061

is hereby dismissed. Chester’s cross-appeal in Case No. A22A0163 is hereby

dismissed as moot.

Court of Appeals of the State of Georgia

Clerk’s Office, Atlanta,____________________

I certify that the above is a true extract from

the minutes of the Court of Appeals of Georgia.

Witness my signature and the seal of said court

hereto affixed the day and year last above written.

, Clerk.

June 21, 2022

06/21/2022
§ 250.102 Drug preparations intended for human use containing certain “coronary vasodilators”. ( a ) ( 1 ) The Food and Drug Administration finds that the following “coronary vasodilators” are extensively regarded by physicians as safe and useful as employed under medical supervision for the management of angina pectoris in some patients: Amyl nitrite. Erythrityl tetranitrate. Mannitol hexanitrate. Nitroglycerin. Potassium nitrite. Sodium nitrite.
( 2 ) Additionally, new-drug applications have been approved for products containing: Inositol hexanitrate. Isosorbide dinitrate. Octyl nitrite. Pentaerythritol tetranitrate. Triethanolamine trinitrate biphosphate (trolnitrate phosphate).
( b ) The Food and Drug Administration also finds that there is neither substantial evidence of effectiveness nor a general recognition by qualified experts that such drugs are effective for any of the other purposes for which some such drugs are promoted to the medical profession in labeling and advertising. In particular, neither clinical investigations nor clinical experience justify any representations that such drugs are effective in the management of hypertension; in the management of coronary insufficiency or coronary artery disease, except for their anginal manifestations; or in the management of the post coronary state, except angina pectoris present after coronary occlusion and myocardial infarction.
( c ) Any preparation containing such drugs that is labeled or advertised for any use other than management of angina pectoris, or that is represented to be efficacious for any other purpose by reason of its containing such drug, will be regarded by the Food and Drug Administration as misbranded and subject to regulatory proceedings, unless such recommendations are covered by the approval of a new-drug application based on a showing of safety and effectiveness.
( d ) Any such drug in long-acting dosage form is regarded as a new drug that requires an approved new-drug application before marketing.
( e ) Any of the drugs listed in paragraph (a)(2) of this section is regarded as a new drug that requires an approved new-drug application. Articles for which new-drug approvals are now in effect should be covered by supplemental new-drug applications as necessary to provide for labeling revisions consistent with this policy statement.
#### § 20.48 Judicial review of proposed disclosure.

Where the Food and Drug Administration consults with a person who will be affected by a proposed disclosure of data or information contained in Food and Drug Administration records pursuant to § 20.47, and rejects the person's request that part or all of the records not be made available for public disclosure, the decision constitutes final agency action that is subject to judicial review pursuant to 5 U.S.C. chapter 7. The person affected will be permitted 5 days after receipt of notification of such decision within which to institute suit in a United States District Court to enjoin release of the records involved. If suit is brought, the Food and Drug Administration will not disclose the records involved until the matter and all related appeals have been concluded.

[42 FR 15616, Mar. 22, 1977. Redesignated and amended at 68 FR 25286, 25287, May 12, 2003]
,2010 HCPCS CORRECTIONS,,,,,,,,
,,,,,,,,,
,,,,,,,,,
CODE,ACTION,EFF DATE,SHORT DESC,LONG DESC,TOS ,BETOS,COV,PRICE,PROC NOTE
,,,,,,,,,
A9581,Add YY to ASC,01/01/2010,,,,,,,
A9582,Add YY to ASC,01/01/2010,,,,,,,
A9583,Add YY to ASC,01/01/2010,,,,,,,
C8923,Change long description,01/01/2010,,"TRANSTHORACIC ECHOCARDIOGRAPHY WITH CONTRAST, OR WITHOUT CONTRAST FOLLOWED BY WITH CONTRAST, REAL-TIME WITH IMAGE DOCUMENTATION (2D), INCLUDES M-MODE RECORDING, WHEN PERFORMED, COMPLETE, WITHOUT SPECTRAL OR COLOR DOPPLER ECHOCARDIOGRAPHY ",,,,,
C8924,Change long description,01/01/2010,,"TRANSTHORACIC ECHOCARDIOGRAPHY WITH CONTRAST, OR WITHOUT CONTRAST FOLLOWED BY WITH  CONTRAST, REAL-TIME WITH IMAGE DOCUMENTATION (2D), INCLUDES M-MODE RECORDING, WHEN PERFORMED, FOLLOW-UP OR LIMITED STUDY ",,,,,
C8928,Change long description,01/01/2010,,"TRANSTHORACIC ECHOCARDIOGRAPHY WITH CONTRAST, OR WITHOUT CONTRAST FOLLOWED BY WITH CONTRAST, REAL-TIME WITH IMAGE DOCUMENTATION (2D), INCLUDES M-MODE RECORDING, WHEN PERFORMED, DURING REST AND CARDIOVASCULAR STRESS TEST USING TREADMILL, BICYCLE EXERCISE AND/OR PHARMOCOLOGICALLY INDUCED STRESS, WITH INTERPRETATION AND REPORT ",,,,,
L8680,Change long description,01/01/2010,,"IMPLANTABLE NEUROSTIMULATOR ELECTRODE, EACH",,,,,
S2118,"Change coverage back to ""I""",01/01/2010,,,,,I,,
S2270,"Change coverage back to ""I""",01/01/2010,,,,,I,,
S3628,"Change coverage back to ""I""",01/01/2010,,,,,I,,
S3711,"Change coverage back to ""I""",01/01/2010,,,,,I,,
S3860,"Change coverage back to ""I""",01/01/2010,,,,,I,,
S3861,"Change coverage back to ""I""",01/01/2010,,,,,I,,
S3862,"Change coverage back to ""I""",01/01/2010,,,,,I,,
S9433,"Change coverage back to ""I""",01/01/2010,,,,,I,,
Order entered September 17 , 2014

In The 

## Court of Appeals Fifth District of Texas at Dallas

No. 05

- 14

- 00521

- CR

GREGORY ALLEN ROBINS ON, JR, Appellant

V.
THE STATE OF TEXAS, Appellee

On Appeal from the 265th Judicial District Court

Dallas County, Tex as Trial Court Cause No. F13

- 34479

- R



### O RDER

On August 12, 2014, this Court ordered the trial court to prepare and file a certification of appellant’s right to appeal. The Court has determined that the certification was signed by the trial court on August 13, 2014, but has not yet been forwarded to this Court by the Dallas County
District Clerk. Accordingly, we ORDER Gary Fitzsimmons, Dallas County District Clerk, to file a supplemental clerk’s record containing the August 13, 2014 certification of appell ant’s right to appeal within TEN DAYS of the date of this order.
We DIRECT the Clerk to send copies of this order, by electronic transmission, to the Honorable Mark Stoltz, Presiding Judge, 265th Judicial District Court; Gary Fitzsimmons, Dallas County Dis trict Clerk; and to counsel for all parties.

/s/ LANA MYERS JUSTICE
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7192 Referred in Senate (RFS)]

<DOC>
118th CONGRESS
  2d Session
                                H. R. 7192

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              June 4, 2024

Received; read twice and referred to the Committee on Homeland Security 
                        and Governmental Affairs

_______________________________________________________________________

                                 AN ACT

 
 To designate the facility of the United States Postal Service located 
 at 333 West Broadway in Anaheim, California, as the ``Dr. William I. 
                  `Bill' Kott Post Office Building''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. DR. WILLIAM I. ``BILL'' KOTT POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at 333 West Broadway in Anaheim, California, shall be known and 
designated as the ``Dr. William I. `Bill' Kott Post Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Dr. 
William I. `Bill' Kott Post Office Building''.

            Passed the House of Representatives June 3, 2024.

            Attest:

                                             KEVIN F. MCCUMBER,

                                                                 Clerk.
```
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 764 Engrossed in House (EH)]

<DOC>
H. Res. 764

                In the House of Representatives, U. S.,

                                                         March 6, 2018.
    Resolved, That the following named Members be, and are hereby, elected to 
the following standing committee of the House of Representatives:
    Committee on Oversight and Government Reform: Mr. Gomez (to rank immediately 
after Mr. Raskin), Mr. Welch, Mr. Cartwright, Mr. DeSaulnier, Ms. Plaskett, and 
Mr. Sarbanes.
            Attest:

                                                                          Clerk.
```
Exhibit 99.14

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                 SECTIION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Tonga Capital Corp (the "Company") on
Form 10-QSB for the period  ending  March 31, 2004 as filed with the  Securities
and Exchange  Commission  on the date hereof (the  "Report").  I , Roger Juhnke,
Chief  Executive  Officer of the Company,  certify,  pursuant to 18 USC 1350, as
adopted pursuant to 906 of the  Sarbancs-Oxley  Act of 2002, that to the best of
my knowledge and belief.

     (1)  The Report fully  complies with the  requirements  of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934: and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and results of operations
          of the Company.



                                     /s/ Roger Juhnke
                                     Roger Juhnke, Chief Executive Officer &
                                                   Chief Financial Officer

Dated: May 12, 2004
<PAGE>
                                                                      EXHIBIT 11


Statement Regarding Computation of Earnings (Loss) Per Share

(in 000's, except per share amounts)

<TABLE>
<CAPTION>

                                                            Unaudited                Unaudited
                                                        Three Months Ended        Six Months Ended
                                                      ---------    ---------   ---------    ---------
                                                      June 29,     June 30,    June 29,     June 30,
                                                        2002         2001        2002         2001
                                                      ---------    ---------   ---------    ---------
<S>                                                  <C>          <C>          <C>         <C>
Weighted average shares outstanding                      48,729       47,847      48,617       47,672
Effect of dilutive securities - options                       -        1,661           -            -
Shares for diluted EPS                                   48,729       49,508      48,617       47,672

Net income (loss)                                     $(199,291)   $     490   $(211,137)   $ (25,593)
Less: Dividend on preferred stock                           563            -         813            -
Income (loss) available to common shareholders        $(199,854)   $     490   $(211,950)   $ (25,593)


Per share amounts:
Basic earnings (loss) per share                       $   (4.10)   $    0.01   $   (4.36)   $   (0.54)
Diluted earnings (loss) per share                     $   (4.10)   $    0.01   $   (4.36)   $   (0.54)
</TABLE>
[No. 15772-5-III.

Division Three.

December 23, 1997.]

#### The State of Washington, *Respondent,*v. Alejandro Zuniga Lemus, *Appellant.*

Appeal from a judgment of the Superior Court for Yakima County, No. 95-1-01907-8, Susan L. Hahn, J., entered May 2, 1996. *Affirmed*by unpublished opinion per Brown, J., concurred in by Kurtz and Kato, JJ.
**Exhibit
        32**
 **Certification
        of Periodic Financial Report**
 **Pursuant
        to 18 U.S.C. Section 1350**


Pursuant
      to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002, each of the undersigned officers of AMCOL
      International Corporation (the “Company”) certifies that the quarterly report on
      Form 10-Q of the Company for the three months ended March 31, 2008 fully
      complies with the requirements of Section 13(a) or 15(d) of the Securities
      Exchange Act of 1934 and information contained in that Form 10-Q fairly
      presents, in all material respects, the financial condition and results of
      operations of the Company.








Date: 
                May 9, 2008
            /s/
                Lawrence E. WashowLawrence
                E. Washow
              Chief
                Executive OfficerDate: 
                May 9, 2008
            /s/
                Gary L. CastagnaGary
                L. Castagna
              Chief
                Financial Officer








33
#### § 26.77 Fees.

Each party shall endeavor to ensure that fees imposed for services under this part shall be commensurate with the services provided. Each party shall ensure that, for the sectors and conformity assessment procedures covered under this part, it shall charge no fees with respect to conformity assessment services provided by the other party.